dr. lopes on the rationale to stop immunotherapy after 2 years in lung cancer
Published 4 years ago • 1.5K plays • Length 1:11Download video MP4
Download video MP3
Similar videos
-
0:39
dr. lopes on the fda approval of nivolumab/ipilimumab in nsclc
-
2:30
dr. lopes on the keynote-042 results of frontline pembrolizumab in nsclc
-
1:12
dr. lopes on standard durations of checkpoint inhibition in metastatic lung cancer
-
5:58
how long to continue immunotherapy
-
1:33
dr. chaft on the rise of immunotherapy in lung cancer
-
0:32
dr. hak choy on radiation and immunotherapy in combination in lung cancer
-
1:13
dr. felip on immunotherapy alone or in combination in lung cancer
-
5:25
immunotherapy in lung cancer
-
1:22
dr. lopes on immunotherapy in head and neck cancer
-
1:18
dr. natale on the evolution of immunotherapy in nsclc
-
1:16
dr. piperdi on immunotherapy in lung cancer
-
1:24
dr. chaft on considerations for restarting immunotherapy in lung cancer
-
1:15
dr. langer on the impact of frontline immunotherapy in lung cancer
-
3:13
dr. ramalingam on side effects associated with immunotherapy in lung cancer
-
1:25
dr. paulson discusses acquired resistance to immunotherapy
-
1:36
dr. rudin on expansion of immunotherapy in lung cancer
-
6:40
chemotherapy/immunotherapy combinations in lung cancer
-
0:58
dr. morris on the role of immunotherapy in metastatic crc
-
1:32
dr. wakelee on immunotherapy versus targeted agents in nsclc